BioCentury
ARTICLE | Company News

CRT Pioneer Fund, ProNAi deal

October 3, 2016 7:00 AM UTC

The fund granted ProNAi exclusive, worldwide rights to develop and commercialize cancer candidate PNT737. The fund will receive $7 million up front and is eligible for up to $319.5 million in milesto...